LAS VEGAS, Sept. 19, 2006 (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today that Taglich Brothers published an updated Samaritan Pharmaceuticals research report on September 13, 2006.
The complete research report should be viewed in its entirety at:
http://www.samaritanpharma.com/images/sampharma-092006.pdf
Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on micro-cap companies. Taglich Brothers defines the micro-cap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.
Samaritan Pharmaceuticals: "We LIV... to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics' for AIDS, Alzheimer's, cancer and heart disease patients. Look at www.samaritanpharma.com. Please register on our Website so we can notify you of upcoming conference calls, news and events.
The Samaritan Pharmaceuticals Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2670
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful.
The company paid Taglich Brothers, Inc. for the creation and dissemination of research reports for the first year a monetary fee of US$18,600 on July 2006, and after the first year of publication will pay a monthly monetary fee of US$1,625 for the creation and dissemination of research reports. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2006. The company undertakes no duty to update forward-looking statements.